I am a science and technology journalist who writes about how biology is shaping our future. Currently, I am a staff writer at OneZero and an adjunct instructor in the Johns Hopkins MA in science writing program. I write often about gene editing, genetic privacy, reproductive technology, neuroscience, and lately, Covid-19. At OneZero, I have reported on the disastrous effects of CRISPR on human embryos, a dubious $1 million pay-to-play clinical trial to reverse aging, the comeback of "young blood" startup Ambrosia, and a DARPA program to make radiation-proof soldiers.


Previously, I served as the associate editor for biomedicine at MIT Technology Review. ​While at Tech Review, I won a Newsbrief Award from the D.C. Science Writers Association for my story about a menstrual cycle-on-a-chip. I was also a finalist for the National Institute for Health Care Management Foundation Print Journalism Award for my enterprising coverage of a U.S. doctor illegally marketing a "three-person" IVF business.


​My stories have also appeared in The Washington Post, New York Times, Wall Street Journal, Scientific American, National Geographic, The Atlantic, and The Baltimore Sun, among others.  


I started my career as a reporter at the Baltimore Business Journal, where I followed the high-profile case of a Maryland cardiologist accused of implanting unnecessary heart stents in patients. I earned my bachelor's degree in journalism at Ohio University and a master's in science writing from Johns Hopkins. I hail from the scenic Laurel Highlands of Western Pennsylvania and now live in Baltimore, Maryland.


© 2020 Emily Mullin

  • Grey Twitter Icon
  • Grey LinkedIn Icon